Stockwinners Market Radar for July 09, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:03 EDT Rapid7 sees Q2 ARR at $814M-$816M, up 8%-9% from last year - Earlier this evening, the company stated: "Rapid7 announced the promotion of three long-tenured sales leaders to General Manager within a new regional model designed to enhance customer engagement, drive stronger customer expansion, and improve efficiency across the sales organization. David Boffa will serve as General Manager of the Americas, David Howorth will serve as General Manager of EMEA, and Rob Dooley will serve as General Manager of APAC. As part of their expanded scope, each of these leaders will be responsible for retention, expansion, and new customer acquisition within their respective regions, and will report directly to Rapid7 Chairman and Chief Executive Officer, Corey Thomas. As Rapid7 continues to execute on its Go To Customer strategy, Chief Customer Officer Larry D'Angelo will step down effective July 12, 2024, to pursue a new opportunity. As part of the integrated, regional customer engagement model, the company does not plan to replace this role. Rapid7 today also provided select preliminary estimated Annualized Recurring Revenue (ARR) results for the three months ended June 30, 2024. Based on currently available information, the Company anticipates second quarter 2024 Annualized Recurring Revenue, or ARR, of $814M - $816M, an increase of 8% - 9% year-over-year, and in-line with the Company's expectations."

20:08 EDT Cathie Wood's ARK Investment buys 177K shares of Blade Air Mobility today

20:07 EDT Cathie Wood's ARK Investment bought 143K shares of Recursion Pharmaceuticals

19:50 EDT Fresh2 Group LTD trading halted, news pending

17:53 EDT VivoPower jumps 16% after securing extension to 34M loan financing facility - Nasdaq-listed B Corp VivoPower International moved up over 20% after announcing earlier on Tuesday, that its independent directors have secured an amendment and extension to its $34M shareholder loan financing agreement following the conclusion of negotiations with the independent directors of its major shareholder, AWN Holdings Limited. As part of the amended terms, VivoPower has consolidated all of its shareholder loans at VivoPower International level, as well as amending all of the outstanding loans to non-current status. This improves the balance sheet profile of VivoPower. AWN will also receive an option to acquire 1,150,000 Tembo shares from VivoPower post business combination with Cactus Acquisition Corp 1 Limited at an exercise price of $1.35 per share. This replaces a previous agreement to issue warrants on VivoPower shares. The exercise price reflects the valuation at which the private investment office backed by a member of the ruling Al Maktoum family of Dubai agreed to invest an advance as announced in June 2023, and takes into account AWN's continued financial support since 2017. It is anticipated that the underlying shares to the Option will represent less than 1.3% of the estimated total number of shares in newly listed Tembo post-deSPAC and these underlying shares will be subject to lock up for at least 6 months. Shares of VivoPower International closed up 4c or 16% to close the session at $2.55 per share.

17:24 EDT HubSpot CTO sells $14.7M in common stock - In a regulatory filing, HubSpot disclosed that its CTO Dharmesh Shah sold 25K shares of common stock on July 8th in a total transaction size of $14.7M.

17:22 EDT Kymera Therapeutics director sells $17.3M in common stock - In a regulatory filing, Kymera Therapeutics disclosed that its director Bruce Booth sold 454K shares of common stock on July 9th in a total transaction size of $17.3M.

17:01 EDT Tyson Foods to sell its Vienna poultry complex to House of Raeford Farms - Tyson Foods has entered into an agreement to sell its Vienna, Georgia poultry complex to House of Raeford Farms, the company announced. Tyson Foods' decision to sell the complex is part of its continued efforts to optimize its plant network, and the company will continue to service customer orders from other production locations. House of Raeford Farms intends to continue poultry processing at the complex utilizing the existing workforce and grower network. The transaction is subject to customary closing conditions including approval by U.S. regulators.

16:57 EDT Ampco-Pittsburgh sees Q2 backlog at $360M-$365M - The company states: "Ampco-Pittsburgh has updated its sales order backlog and expects to report that its Air and Liquid Processing segment achieved a record level of new orders in the quarter ended June 30, 2024. Order activity surged more than 50% versus the quarter ended March 31, 2024, to achieve the highest quarterly order intake in the segment's history. The Corporation expects total backlog for the quarter ended June 30, 2024, to be in the range of $360 to $365 million, which represents sequential growth of 3.2% to 4.6% compared to the quarter ended March 31, 2024."

16:55 EDT Ampco-Pittsburgh announces commercial contract wins - Ampco-Pittsburgh announced that its wholly-owned subsidiary, Union Electric Steel Corporation, has been selected to supply the initial provisioning of rolls for two new rolling mill projects under construction. The roll contracts for these new mills are: A new cold mill for Ternium Mexico S.A. de C.V. - Pesqueria, a major North American steel producer, with roll deliveries expected to begin in the first half of 2025 valued at approximately $6.7 million; and A new plant being built in Scandinavia by a major European OEM mill builder requiring rolls to be delivered in the first half of 2025 valued at approximately $5.0 million.

16:49 EDT Aehr Test Systems jumps 15% to $14.25 after raising FY24 revenue guidance - Shares of Aehr Test Systems are up 15% or $1.84 at $14.25 after the company pre-announced its Q4 revenue at $16.6M, resulting in FY24 revenue of $66.2M - above consensus on two estimates of $65.1M and the management's previous outlook of $65M.

16:39 EDT Nvidia CEO sells $30.7M in common stock as part of option exercise - In a regulatory filing, Nvidia disclosed that its CEO Jen Hsun Huang sold 240K shares of common stock on July 5th as part of option exercise in a total transaction size of $30.7M.

16:37 EDT LegalZoom CEO Dan Wernikoff to depart, chairman Jeffrey Stibel to succeed - LegalZoom announced that the company's current chairman of the board of directors, Jeffrey Stibel, has been named LegalZoom's next CEO, effective immediately. LegalZoom has also appointed John Murphy as the lead independent director of the board. As part of this transition, current CEO Dan Wernikoff will be departing the company, including resigning from the board. The company said that the board and Wernikoff decided that now is the right time for this transition, as the company increases its focus on shifting towards subscription-based revenue to drive long-term profitable growth.

16:32 EDT Calumet Specialty Products unitholders approve conversion to C-Corporation - Calumet Specialty Products Partners announced that its unitholders voted to approve the previously announced conversion of its structure from a master limited partnership to a C-Corporation, pursuant to which the unitholders of the Partnership will become shareholders of Calumet upon closing of the Conversion.

16:31 EDT Granite awarded $16M contract to improve Salinas traffic flow - Granite has been awarded an approximately $16 million contract by the City of Salinas to improve traffic flow on a key thoroughfare between residential areas and Highway 101. This project will enhance safety for pedestrians and bicyclists commuting to and from the adjacent elementary school. Granite will widen East Boronda Road into a four-lane roadway (two lanes in each direction) and construct a multi-lane roundabout at the McKinnon Street intersection. The project includes construction of bioretention facilities, buffered bike lanes, bus pullouts, sidewalks, ADA-compliant access ramps, storm drain lines, sanitary sewer lines, street lighting, landscaping, and other improvements. Project funding comes from the City of Salinas and will be included in Granite's second-quarter CAP.

16:30 EDT NYSE to commence delisting proceedings against Getaround - New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Getaround, Inc from the NYSE. Trading in the Company's common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's common stock pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.

16:25 EDT Arcutis Biotherapeutics trading halted, news pending

16:22 EDT Gatos Silver reports Q2 CLG mine silver equivalent production 2.3M ounces - Gatos Silver announced production results for the quarter and six months ended June 30 at its 70%-owned Cerro Los Gatos, or CLG, mine in Mexico. Silver equivalent production for the second quarter of 2024 was 3.88 million ounces, 18% higher than the second quarter of 2023. Silver production was 2.3M ounces, 15% higher than the comparable quarter of 2023. Zinc production increased by 29% compared with the second quarter of 2023 as a result of higher throughput, higher grades and higher recovery resulting in a record quarterly production of 19.1M pounds. Lead production and gold production increased by 24% and 14%, respectively, compared with the second quarter of 2023 due to higher throughput and grades. The company continues to expect both silver equivalent and silver production to be in the top half of its previously announced guidance ranges of 13.5M to 15M ounces and 8.4M to 9.2M ounces respectively for the full year in 2024. The processing plant is reliably performing above 3,500 tons per operating day with no reduction in metallurgical recoveries. The CLG team is focused on first consistently maintaining and then gradually increasing daily mine production rates by implementing various optimization and improvement projects across the maintenance and mine operation functions over the next six to 12 months. As of June 30, the company and the Los Gatos Joint Venture reported cash and cash equivalents of $82.5M and $45.5M, respectively.

16:20 EDT Trinity Biotech names Louise Tallon CFO, backs guidance - Trinity Biotech announces the appointment of Louise Tallon as Chief Financial Officer. Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024. With the CFO transition we also reiterate our financial guidance and intend to achieve approximately $20M of annualized run-rate EBITDASO on annualized revenues of approximately $75M by Q2 2025." Louise Tallon responded, "I'm excited to join the Trinity Biotech team and look forward to contributing to its exciting vision to become a highly profitable organisation, intent on executing its development and launch of a next generation CGM device."

16:17 EDT Bowman Consulting announces executive promotions - Bowman Consulting announced that its Board of Directors has approved the promotion of two senior executives and ratified a new four-year contract with its chief financial officer. Michael Bruen, who served as the Company's chief operating officer, has been promoted to president, a role previously held by Gary Bowman, who retains the titles of chief executive officer and chairman. Dan Swayze, who served as executive vice president and division manager, has been promoted to the role of chief operating officer. In connection with the promotion, Swayze becomes an executive officer of the Company. Bruce Labovitz, executive vice president and chief financial officer has entered into a new four-year contract with the Company which runs through June 30, 2028.

16:16 EDT MSG Sports names Jamaal Lesane as COO - Madison Square Garden Sports announced that Jamaal Lesane has been named COO. Lesane previously served as MSG Sports' Executive Vice President and General Counsel since March 2022. Lesane joined the MSG Family of Companies in 2008 and has served in roles of increasing responsibility over more than 15 years.

16:14 EDT Chipotle: Jamie McConnell to become Chief Accounting Officer on Jan. 1, 2025 - Jamie McConnell will assume the role of Chief Accounting and Administrative Officer on January 1, 2025, reporting to Rymer. Since joining Chipotle in 2018, McConnell has reported directly to and been mentored by Hartung. She currently serves as Vice President, Controller, with responsibility for the Corporate Accounting, Financial Reporting, Tax, Internal Audit, Accounting Shared Services, Licensing and Payroll functions. McConnell's breadth of finance experience and Chipotle tenure will further support a smooth transition.

16:11 EDT Chipotle CFO Jack Hartung to retire, effective March 31, 2025 - Chipotle Mexican Grill announced that after nearly 25 years with the company, Jack Hartung has decided to retire, effective March 31, 2025. Hartung has served as CFO since 2002. The company also reported that Adam Rymer, a 15-year Chipotle veteran will assume the role of CFO, beginning January 1, 2025. Rymer joined Chipotle in 2009 and currently serves as Vice President of Finance, overseeing its Corporate Finance, Field Finance and Investor Relations functions. During his entire tenure at Chipotle, he has reported directly or indirectly to and been mentored by Hartung, as well as held a variety of finance positions of increasing responsibility. Rymer will serve on Chipotle's executive leadership team and report to Brian Niccol, Chairman and CEO. Hartung will continue in his current position through the end of the year and will remain with the company until March 31, 2025 to help ensure a smooth transition.

16:07 EDT Amneal launches launch of FOCINVEZ - Amneal Pharmaceuticals announced the launch of FOCINVEZ, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin, and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. "We continue to launch differentiated complex products that are clinically impactful," said Sean McGowan, Vice President, Biosimilars and Branded Oncology. "This is the second ready-to-use injectable we have launched this year that offers hospitals and oncology clinics a new presentation format that can improve pharmacy efficiency. These new 505(b)(2) injectables represent a new vector of growth for our expanding injectables portfolio."

16:06 EDT - Illumina announced that effective July 9, it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. The Fluent team will join Illumina, and PIPseq V will be integrated into Illumina's product portfolio. The company plans to build on Fluent's technology to develop full end-to-end solutions for single-cell analysis. The acquisition closed on July 9, and has been funded with cash on hand.

16:06 EDT UPS names Brian Dykes as new CFO - UPS announced the appointment of Brian Dykes as its new Executive Vice President and CFO. Effective immediately, he will be responsible for UPS's financial strategies and will lead the global finance organization, including planning, treasury, tax, financial reporting, financial operations, and investor relations. Dykes has spent more than 25 years with UPS, most recently serving as Senior Vice President, Global Finance and Planning, since April 2023.

16:02 EDT Bassett Furniture increases quarterly dividend 11% to 20c per share - Bassett Furniture announced that its board of directors has declared a regular quarterly dividend of 20c per share of common stock, payable on August 30 to shareholders of record at the close of business on August 16 which represents an 11% increase over the prior quarterly dividend.

16:01 EDT Playa Hotels & Resorts reports no significant damages after Hurricane Beryl - Playa Hotels & Resorts announced that following a preliminary assessment, the Company's resorts in the Caribbean and Mexico did not sustain significant damage from Hurricane Beryl. All of the Company's resorts are currently open, operational and welcoming our arriving guests.

16:00 EDT Macy's names Keith Credendino CIO - Macy's, Inc. announced that Keith Credendino has been named Chief Information Officer effective August 4, 2024. Credendino who is currently Senior Vice President of Technology Product Development, Customer Experience, will succeed Laura Miller as Macy's, Inc.'s new CIO and join the company's Corporate Strategy Group, reporting to Adrian V. Mitchell, Chief Operating Officer and Chief Financial Officer. Miller joined Macy's, Inc. in 2021 and built a high performing, agile technology leadership team, recruiting, retaining, and developing talent to ensure the company's future success. She has been instrumental in modernizing technology systems, operations, and the company's omnichannel digital offerings to enhance customer and colleague experiences. She will retire with a strong successor in place to build upon the achievements to date. "The entire Macy's, Inc. family wishes Laura well on her retirement and thanks her for the many accomplishments over her transformative tenure," said Adrian V. Mitchell, Macy's, Inc.'s Chief Operating Officer and Chief Financial Officer. "As our new CIO, Keith will continue to simplify and modernize our technology stack as part of our company's growth strategy, 'A Bold New Chapter.' There is still much work to be done and Tony Spring, our Chairman and Chief Executive Officer, our Board of Directors, and I are confident that with Keith's authentic, collaborative, and results-oriented leadership style, he will help lead Macy's, Inc. into the future as an even more agile company, responsive to today's discerning consumer."

15:16 EDT Kelly Services CFO to retire - In a regulatory filing, Kelly Services disclosed that on June 8, Olivier Thirot, the Chief Financial Officer of the company, informed the company of his intention to retire as an officer in Q1 of 2025. "The Compensation and Talent Management Committee of the Company's Board of Directors, which is responsible for executive development and succession, has commenced a process to identify and recruit a successor to serve as the company's Chief Financial Officer. Mr. Thirot joined Kelly in 2008 as vice president of finance for Kelly EMEA region, bringing with him more than 25 years of international experience in the areas of treasury, tax, compliance, budget forecasting and strategic planning. In 2011 he assumed the additional responsibility for Kelly's APAC region. Mr. Thirot was named chief financial officer in 2016. The material terms of Mr. Thirot's separation arrangements, including transition plans, will be reported at the time they are finalized," the filing stated. Reference Link

14:04 EDT Cosmos Health announces contract manufacturing agreement with Humacology - Cosmos Health announced that its wholly-owned subsidiary, Cana Laboratories, has secured a contract manufacturing agreement with Australian-based wellness company Humacology. "Humacology is currently embarking on a global expansion drive and has entrusted Cana to manufacture up to 500,000 units of its CBD products. This is the second consecutive agreement announced by Cana over the past week, following its previously announced contract manufacturing agreement with Provident Pharmaceuticals for 4.32 million units of DE3-SOLE, which is used to address vitamin D deficiency by helping the body absorb calcium and promote overall health," the company stated. Greg Siokas, CEO of Cosmos Health, added: "We are currently scaling up our high-margin contract manufacturing business at a rapid pace, as evidenced by our back-to-back agreements with Humacology and Provident. Cosmos is close to securing several more highly profitable contract manufacturing agreements and will provide updates as soon as any new agreements materialize."

13:31 EDT Fifth Third expands into Alabama - Fifth Third is entering the Alabama market and announced the opening of a commercial banking office in Birmingham. The office is an expansion of its Fifth Third's operations in Georgia. The new office currently has commercial and treasury management capabilities and will expand to include a Fifth Third Private Bank office. Fifth Third's strategic expansion in the Southeast, now in its seventh year, originally focused on Tennessee, Georgia, the Carolinas and Florida, and now includes Alabama. Across its Southeast footprint, Fifth Third delivers for customers and local communities by adding financial centers and offering banking services to commercial, treasury management, and wealth and asset management clients. "We are proud to plant our flag in Birmingham," said Randy Koporc, regional president for Fifth Third in Georgia and Alabama. "The state of Alabama is an extremely attractive and important region for us. Our long-term growth plan includes attracting and retaining talent who understand Birmingham's unique market landscape within the Commercial and Private Bank divisions so we can meet our clients' needs today, and in the future."

13:22 EDT Volkswagen cuts view of 2024 passenger car operating return on sales to 6.5%-7% - Volkswagen stated: "The Supervisory Board of AUDI AG resolves to support an information and consultation process at the Brussels site. In this process, the Board of Management of Audi Brussels S.A./N.V. will work together with the responsible social partners to develop solutions for restructuring the site. At the end of this process, the plant may among other things be closed down. Expected expenses from these matters and other unplanned expenses in the Volkswagen Group have resulted in an adjustment to the 2024 forecast. The Board of Management of Volkswagen AG has been informed today that the Supervisory Board of AUDI AG, against the background of the development of demand for the Audi Q8 e-tron model family in certain markets, has decided at its meeting today to support an information and consultation process at the Brussels site as required by Belgian law. In this process, the Board of Management of Audi Brussels S.A./N.V. is working together with the responsible social partners to develop solutions for the site. At the end of this process, the site may among other things be closed down. The expenses expected as a result of alternative uses or a plant closure, which are expected to be accrued in the third quarter, in conjunction with the other unplanned expenses in the Volkswagen Group, will have a significant impact on the operating result of the Volkswagen Group in the 2024 financial year. The other unplanned expenses comprise various items that had a negative impact on the Volkswagen Group's operating result in the second quarter. These resulted, among other things, from exchange rate losses in connection with the deconsolidation of Volkswagen Bank Rus in the Financial Services Division and from expenses in connection with the planned closure of the gas turbine business of MAN Energy Solutions. In addition, as announced in April, Volkswagen recognized provisions of EUR0.9 billion for termination agreements as part of the sustainable reduction in administrative personnel costs at Volkswagen AG. In total, all of the aforementioned matters will lead to a total burden on the operating result of up to EUR2.6 billion in the 2024 financial year, with the matters mentioned in the last paragraph already being recognized as expenses in the second quarter. The effects mainly relate to the Volkswagen Group, the Brand Group Core, the Brand Group Progressive and the Financial Services Division. The Brand Group Sport Luxury (Porsche AG) and the Brand Group Trucks (TRATON SE) are not affected by the aforementioned expenses. In view of the additional earnings effects of up to EUR1.7 billion above and beyond the termination agreements at Volkswagen AG, Volkswagen Group does not expect to be able to compensate for these in the current financial year and is therefore adjusting the annual forecast for 2024 for the Volkswagen Group and the Passenger Cars Business Area and now expects an operating return on sales in the range of 6.5% and 7.0% (previously: 7.0% to 7.5%). The forecast for the other key figures remains unchanged. Volkswagen will publish its half-year financial report on August 1."

12:38 EDT Delta, Riyadh Air sign strategic cooperation memorandum of understanding - Delta Air Lines and Riyadh Air have signed a Strategic Cooperation Memorandum of Understanding with the goal of introducing a broad range of benefits for customers traveling between North America, the Kingdom of Saudi Arabia and destinations beyond. The agreement serves as the foundation for a strategic partnership that will enable both airlines to strengthen connectivity, expand their networks and drive future growth. The agreement envisions a long-term relationship, subject to regulatory approvals, that includes interline and codeshare connectivity, as well as a deeper partnership encompassing loyalty, customer experience, digital transformation and broader aviation services such as maintenance, repair and overhaul services, ground handling and training. In the future, the airlines intend to explore an immunized joint venture to further expand the partnership and allow collaboration on network planning and growth in the region. Both airlines are committed to driving the best sustainability practices throughout their operations as they transform the future of travel. The partnership will open new destinations in Saudi Arabia and beyond for Delta customers, including future nonstop service on Delta between the U.S. and King Khalid International Airport in Riyadh. It will provide leisure travelers with a new region of the world to explore while creating new opportunities for business travelers to Riyadh, a G20 capital city, plus destinations beyond. And it will offer Delta's leading North American network for Riyadh Air customers, offering convenient access to hundreds of destinations in the U.S. and beyond with Delta's famous reliability and elevated service.

12:11 EDT Accenture acquires True North Solutions, terms not disclosed - Accenture has acquired True North Solutions, a provider of industrial engineering solutions headquartered in Calgary, Alberta, to help clients produce and transport energy more safely and efficiently. True North Solutions expands Accenture's expertise in operational technology for clients in the oil and gas and mining industries. OT is the hardware and software systems with which companies run and control physical equipment and facilities, such as pipelines, refineries, plants and mines. Accenture will help clients better connect their OT to their enterprise IT systems, for example, to optimize the output and safety of existing equipment and facilities through real-time data analytics. Accenture will also work with the True North Solutions team to engineer and commission new field operations and facilities where OT and IT are seamlessly integrated and processes are digitized from the start. True North Solutions' services encompass engineering and commissioning, industrial automation solutions, enterprise asset management, OT cybersecurity, and digital infrastructure for industrial telecommunications. They bring a team of 95 experts in automation, instrumentation and electrical engineering to Accenture, who will join the company's digital engineering and manufacturing service, Industry X. Terms of the transaction were not disclosed.

12:01 EDT Studio City falls -11.2% - Studio City is down -11.2%, or -85c to $6.71.

12:01 EDT Williams-Sonoma falls -50.1% - Williams-Sonoma is down -50.1%, or -$142.91 to $142.28.

12:00 EDT Arlo Technologies rises 12.7% - Arlo Technologies is up 12.7%, or $1.75 to $15.55.

11:50 EDT Karyopharm granted FDA orphan designation in Ewing sarcoma - The FDA granted orphan designation to Karyopharm's padnarsertib as a treatment of Ewing sarcoma, according to a post to the agency's website. Reference Link

11:24 EDT Fifth Third enters into settlement agreement with CFPB - Fifth Third Bank announced t has reached a comprehensive settlement agreement with the Consumer Financial Protection Bureau to resolve both its litigation related to sales practices and an investigation into the Bank's auto finance servicing activities. Fifth Third has agreed to pay a $15M fine for sales practices and a $5M fine for auto finance servicing activities. This agreement requires Fifth Third to maintain existing policies and develop compliance plans. The Bank will also work with the Bureau's supervisory arm to develop and implement remediation plans for any customers whom the Bank has not already remediated for these issues. The settlement resolves disputed sales practices issues related to a limited number of accounts opened beginning in 2010 and ending in 2016. The settlement also addresses the CFPB's concerns about an auto collateral protection insurance program that Fifth Third voluntarily discontinued in January 2019. "Today's settlement concludes both the sales practices litigation with the CFPB, and its separate investigation into certain auto finance servicing activities related to a collateral protection insurance program that the Bank shut down in 2019 before the CFPB began its investigation," said Susan Zaunbrecher, chief legal officer of Fifth Third. "We have already taken significant action to address these legacy matters, including identifying issues and taking the initiative to set things right. We consistently put our customers at the center of everything we do. We are pleased to put these historical matters behind us so we can continue to focus on creating sustainable long-term value for our shareholders, customers, employees and in our communities."

10:55 EDT Correction: Williams-Sonoma up 1%, shares reflect two-for-one stock split - Shares of Williams-Sonoma are up 1%, or $1.47, to $144.06 in morning trading as the company's two-for-one stock split took effect. Each stockholder of record on June 27 received one additional share of common stock for each share of common stock held, payable after the close of market on July 8. Trading commenced on a split-adjusted basis at market open today. The stock did not trade down 49.8% this morning as previously reported.

10:15 EDT CFPB issues order against Fifth Third Bank - On July 9, the Consumer Financial Protection Bureau issued an order against Fifth Third Bank, a national bank that, among other things, offers and services motor vehicle loans to consumers directly and through a variety of vehicle dealers. The order requires Fifth Third to come into compliance with the law, pay redress, and pay a $5M civil money penalty, the CFPB announced. Reference Link

10:08 EDT UiPath sinks 6% to $12.03 after announcing 10% workforce reduction

10:07 EDT Chijet Motor Co Inc trading resumes

10:02 EDT BAE Systems delivers Advanced Radar Warning Receivers to U.S. Air Force - BAE Systems is delivering AN/ALR-56M Advanced Radar Warning Receivers to the U.S. Air Force to help protect C-130J Super Hercules aircraft missions under contracts worth $133 million with the Defense Logistics Agency. The company has delivered more than 1,700 radar warning receivers for F-16 Fighting Falcons and C-130Js over three decades, providing situational awareness and self-defense capabilities that have proven themselves in combat by saving lives and enhancing mission success.

10:01 EDT Helios Technologies falls -13.8% - Helios Technologies is down -13.8%, or -$6.40 to $39.93.

10:00 EDT Arlo Technologies rises 11.1% - Arlo Technologies is up 11.1%, or $1.53 to $15.33.

10:00 EDT Jumia Technologies rises 19.2% - Jumia Technologies is up 19.2%, or $1.62 to $10.09.

09:48 EDT Jumia Technologies rises 12.2% - Jumia Technologies is up 12.2%, or $1.03 to $9.49.

09:47 EDT Nuscale Power falls -5.6% - Nuscale Power is down -5.6%, or -76c to $12.93.

09:47 EDT Helios Technologies falls -10.5% - Helios Technologies is down -10.5%, or -$4.86 to $41.48.

09:45 EDT Zapp Electric Vehicles Group Ltd trading resumes

09:40 EDT Zapp Electric Vehicles Group Ltd trading halted, volatility trading pause

09:34 EDT Annovis Bio Inc trading halted, volatility trading pause

09:30 EDT Catcha Investment Corp trading halted, volatility trading pause

09:25 EDT Verisk Analytics launches ISO Experience Index - To help insurers, Verisk has launched its ISO Experience Index, an innovative tool designed to modernize how actuaries in the insurance industry analyze risk patterns. The ISO Experience Index addresses the increasing volatility and scale of loss patterns in the industry, offering a responsive and up-to-date indicator of observed underwriting experience.

09:22 EDT Asure Software enters partnership with MyHRScreens - Asure has signed a strategic partnership agreement with MyHRScreens. This collaboration aims to expand access to comprehensive background screening solutions to small and mid-sized businesses, facilitating a safer and more efficient hiring process. Through this partnership, Asure will offer MyHRScreens' advanced background screening capabilities to give their small and mid-sized business clients easy access to robust screening services, including criminal history checks, employment verifications, education verifications, and drug testing. These services enable businesses to make informed hiring decisions quickly and with confidence.

09:21 EDT Silynxcom receives $500,000 in orders from Israel Defense Forces - Silynxcom received product orders of $500,000 from the Israel Defense Forces for its advanced military headset system family of products.

09:18 EDT FingerMotion debuts solutions for nationwide emergency response managemet - FingerMotion announced that its contractually controlled subsidiary, Shanghai JuiGe Information Technology, has ventured into the development of crisis and emergency response solutions specifically for collaboration with dispatchers, first-responders and healthcare agencies in the event of emergency situations in China. JiuGe Technology has received its first order for its Advanced Mobile Integrated Command and Communication Platform, to be installed in all vehicles and apparatuses involved in the country's civil emergency crisis program. The C2 Platform is designed to efficiently unify various disaster communication systems, such as emergency vehicles, satellites, mobile cell towers and unmanned aerial vehicles. The platform integrates voice, video, and data into a unified interface, streamlining workflows and offering comprehensive insights for enhanced decision-making with better focus, accuracy and speed. The C2 Platform is expected to be initially installed into the Mobile Command and Communication Vehicle, a technological collaboration with SAIC Motor Corp

09:16 EDT GoPro partners with C&S in Japan for new distribution network - GoPro announced a new distribution partnership with SoftBank Group's SB C&S Corporation in Japan to sell GoPro products through one of the largest sales networks in the region. SB C&S will distribute GoPro cameras and accessories to retail outlets across Japan, including their own directly managed SoftBank stores, plus two of Japan's largest consumer electronics retailers - Yodobashi and Yamada.

09:15 EDT IGC Pharma announces preclinical data from TGR-63 analysis - IGC Pharma announced preclinical data demonstrating TGR-63's potential as an effective treatment for Alzheimer's disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer's murine models both indicate that TGR-63 has the potential to cross the blood-brain barrier in humans. These findings build on earlier results demonstrating TGR-63's efficacy in reducing amyloid plaque in Alzheimer's mouse models. The preclinical studies on TGR-63 included an analysis of the partition coefficient in an aoctanol-water assay the partition coefficient calculated as Log Poctanol/water, indicated that LogP=0.1, which the company says suggests that TGR-63 possesses favorable properties for penetrating the blood-brain barrier, a critical step in accessing brain tissue. Additionally, mass spectrometry analysis of brain tissue samples from TGR-63-treated mice confirmed the presence of the compound in the brain, validating its ability to cross the blood-brain barrier in mice and potentially in humans. Furthermore, the safety profile of TGR-63 was evaluated through extended studies in mice. Mice received daily doses of TGR-63 for eight months without exhibiting any adverse effects. Comprehensive examinations of major organs, including the liver, heart, spleen, and kidneys, revealed no signs of toxicity, inflammation, or cell death, indicating biocompatibility and safety. IGC continues to progress TGR-63 towards clinical trials, representing a significant advancement in Alzheimer's treatment research.

09:13 EDT Myriad Genetics announces second foundational patent granted for MRD - Myriad Genetics announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease, MRD, assay to market. U.S. patent no. 12,024,749, entitled "Combinatorial DNA Screening," covers Myriad's groundbreaking platform MRD technology, which enables highly sensitive and specific tumor-informed, sequencing-based MRD assays such as Precise MRD. Specifically, the patented method relates to detecting circulating tumor DNA in patient fluid samples, including blood and plasma.

09:12 EDT P3 Health Partners, Innovaccer team to expand value-based care initiatives - Innovaccer a healthcare AI company, announced a new strategic partnership with P3 Health Partners ...This partnership marks a significant milestone in advancing value-based care initiatives aimed at improving patient outcomes, optimizing costs, and enhancing the patient and clinician experience..."Our strategic partnership with Innovaccer accelerates our ability to empower providers with the necessary tools and data needed to better serve and support patients," said Dr. Aric Coffman, CEO of P3 Health Partners. "Through the Innovaccer Healthcare AI Platform we will further reduce time spent on administrative tasks for our providers, enhance our data integration and analytics to better serve our payer partners, improve the quality of the care patients receive, and better manage costs across the continuum of care."

09:10 EDT Global Mofy Metaverse establishes Century Mofy Vocational Education Institute - Global Mofy Metaverse announced it has established the Century Mofy Vocational Education Institute to meet the surging demand for trained AI talent and computer graphic artists. Haogang Yang, CEO of Global Mofy, stated, "The AI market is evolving at an unprecedented pace, creating a critical shortage of trained talent worldwide. We aspire to eliminate this growth barrier by fulfilling the rising demand for skilled professionals. Our visionary mission is to drive the advancement of AIGC technology and cultivate creative leaders who will together shape the future of digital entertainment. By seamlessly blending industry practices with rigorous educational standards, we aim to provide students with unparalleled learning experiences and establish new benchmarks in vocational education."

09:09 EDT Royal Gold unit RGLD Gold sold approximately 52,600 GEOs in Q2 - Royal Gold announced that its wholly owned subsidiary, RGLD Gold AG, sold approximately 52,600 gold equivalent ounces or GEOs, comprised of approximately 39,200 ounces of gold, 593,200 ounces of silver and 1,500 tonnes of copper related to its streaming agreements during the three-month period ended June 30 (the . The company had approximately 12,000 ounces of gold and 450,500 ounces of silver in inventory at June 30. RGLD Gold AG's average realized gold, silver and copper prices for the second quarter were $2,339 per ounce, $28.46 per ounce and $9,475 per tonne or $4.30 per pound, respectively. Cost of sales was approximately $459 per GEO for the second quarter. Cost of sales is specific to the company's streaming agreements and is the result of the company's purchase of gold, silver or copper for cash payments at a set contractual price, or a percentage of the prevailing market price of gold, silver or copper when purchased.

09:08 EDT Fatburger, Round Table Pizza announce co-branded concept headed to Utah - FAT Brands, parent company of Fatburger, Round Table Pizza, and 16 other restaurant concepts, announces a new development deal set to bring the iconic California-based pizza and burger chains to Utah. In partnership with franchisee Blacksheep Hospitality Group, the new deal will bring a total of 12 co-branded Fatburger and Round Table Pizza franchised restaurants to the Beehive State over the next six years, with the first unit set to open in 2025. "Since debuting the Fatburger and Round Table Pizza co-branded pairing last year, we now have over 50 plus units in the development pipeline," said Taylor Wiederhorn, Chief Development Officer of FAT Brands. "This momentum can be attributed to the model's success right out of the gate in Texas. Shelby Jobe and his team opened the first co-branded store in Texas, and we are confident that he will be just as successful in expanding the concept throughout Utah with Blacksheep Hospitality Group, LLC."

09:06 EDT Nuwellis announces new clinical evidence on Aquadex system - Nuwellis announce that new clinical evidence demonstrating the efficacy of its Aquadex system will be presented at the Heart Failure Society of America Annual Scientific Meeting, taking place September 27-30, 2024, in Atlanta, Georgia. The study, conducted by Dr. Wayne Old, MD, an advanced heart failure cardiologist at Sentara Health, based out of Sentara Norfolk General Hospital in Norfolk, Va., highlights the benefits of Aquadex ultrafiltration therapy for heart failure patients experiencing fluid overload who have not responded to traditional diuretic treatments. The research underscores Aquadex's ability to effectively manage fluid levels, providing a critical therapeutic alternative for this challenging patient population.

09:04 EDT DDC Enterprise appoints Betty Liu to Advisory Board - DDC Enterprise (DDC) announced the appointment of Ms. Betty Liu as a member of the Advisory Board of the company. Ms. Liu will leverage her extensive network and experience in content, direct-to-consumer brands, business leadership and the US capital markets to help guide DayDayCook's strategic initiatives and growth. She most recently served as the Executive Vice Chairman of the New York Stock Exchange and Chief Experience Officer for its parent company, Intercontinental Exchange (ICE).

09:03 EDT New Fortress Energy sells LNG facility in Miami to Pennybacker Capital - New Fortress Energy has entered into a definitive agreement to sell a small-scale LNG business based in Miami, Florida, to Pennybacker Capital, a real assets investment manager. Financial terms were not disclosed. The transaction is expected to close in Q3 subject to customary terms and conditions. The Miami-based business includes a small-scale liquefaction facility capable of producing 8,300 MMBtu of LNG per day with onsite storage capacity of ~1,000 cubic meters.

09:03 EDT Ansys listed in AWS 'ICMP' for U.S. Federal Government - Ansys (ANSS) announced that it is listing Ansys STK in the AWS Marketplace for the U.S. Intelligence Community. ICMP is a curated digital catalog from Amazon Web Services (AMZN) that makes it easy to discover, purchase, and deploy software packages and applications from vendors that specialize in supporting government customers.

08:51 EDT Wearable Devices says Fortune 500 customer purchases evaluation license for MDK - Wearable Devices announced that a Fortune 500 consumer electronics corporation has purchased a special license for its Mudra Development Kit to evaluate certain deep-level capabilities. The MDK enables developers to create unique experiences with the Mudra Band and Mudra Application Programming Interface. This powerful toolset will enable the Customer's development team to seamlessly integrate advanced functionalities into their upcoming products, enhancing user experience through innovative gesture control technology.

08:48 EDT California Water Service subsidiary plans to invest $1.6B in California systems - California Water Service submitted Infrastructure Improvement Plans for its California districts from 2025-2027 in its General Rate Case filing with the California Public Utilities Commission. The application also proposes a Low-Use Water Equity Program, which would decouple revenue from water sales, to assist low-water-using, lower-income customers. The required, triennial filing begins an approximately 18-month review process by the CPUC, an independent state agency, which will analyze the Infrastructure Improvement Plans, operating budget proposals, and Low-Use Water Equity Program to establish water rates for 2026-2028 that reflect the actual cost of providing safe, reliable water service. Associated rates set by the CPUC would become effective no sooner than January 2026. In the plans, Cal Water proposes to invest more than $1.6 billion in its districts from 2025-2027, including approximately $1.3 billion of newly proposed capital investments. About 46% of the proposed new infrastructure improvements would replace aging water pipelines, which is designed to enhance water supply reliability to support customers' and firefighters' everyday and emergency needs. The plans also include, among other projects: Water quality upgrades to treat for existing and newly regulated contaminants. Infrastructure replacements to help pump and deliver water reliably. Equipment such as generators to help withstand power outages and shutoffs, and solar installation projects to help reduce Cal Water's dependency on the electric power grid and its environmental footprint. Physical and cyber security and safety enhancements to help protect facilities, customers, and employees. Water supply initiatives to help safeguard long-term reliability and sustainability of water sources. Advanced Metering Infrastructure to aid conservation efforts and enhance water-use efficiency. Cal Water's proposed Low-Use Water Equity Program would decouple revenue from water sales across its regulated service areas. The program is designed to work in conjunction with Cal Water's proposed progressive, four-tier rate design and sales forecast proposals to enhance affordability-particularly for low-use and low-income customers-plus reinforce conservation goals, while providing the utility an opportunity to recover its authorized revenue requirement in a timely manner. To support these investments, Cal Water has proposed to the CPUC to increase 2026 total revenue by $140.6 million, or 17.1%. This increase is based on 2026 authorized revenue at current rates. Cal Water also proposes to increase revenue by $74.2 million, or 7.7%, in 2027; and $83.6 million, or 8.1%, in 2028. The company also continues to focus on enhancing efficiency and reducing expenses to help offset the cost of upgrades.

08:39 EDT Getaround gets $20M commitment from Mudrick, intent to convert convertible debt - Getaround announced it received a written commitment from Mudrick Capital Managemen to provide $20 M in additional capital on or prior to July 26 pursuant to the company's existing debt facility with Mudrick Capital. Getaround also received written notice from Mudrick Capital of its intention to convert a minimum of $10M worth of its outstanding 8.00%/9.50% Convertible Senior Secured PIK Toggle Notes due 2027 at an as-adjusted conversion price of 25c per share, within 45 days after the company's 2024 Annual Stockholder Meeting scheduled to take place on July 31. The amendment of such conversion price to 25c per share is subject to stockholder approval at such annual meeting and required pursuant to the terms of the previously disclosed super priority promissory note between the Company and Mudrick Capital. "We are grateful for the continued vote of confidence from Mudrick Capital reflected in this additional investment and their stated intention to convert a portion of the outstanding convertible debt as we continue to make significant progress on our path to profitability," said Eduardo Iniguez, Getaround's Chief Executive Officer

08:39 EDT CytoDyn announces settlement with Amarex Clinical Research - CytoDyn announced that it has settled its lawsuit against Amarex Clinical Research, the Company's former Contract Research Organization. The material terms of the settlement are as follows: Amarex will pay $12,000,000 to CytoDyn, $10,000,000 was paid upon execution of the agreement and the remainder to be paid within the next 12 months; the surety bond, valued at $6,500,000, will be released to CytoDyn in full; all sums Amarex had claimed as due and payable, aggregating to approximately $14,000,000, will be eliminated, with no payment required from CytoDyn; and a mutual release of claims, resolving all legal claims between the parties.

08:37 EDT Hark Capital closes on $645M in capital commitments for Fund IV - P10 announced that its affiliated manager, Hark Capital announced the final closing of Hark Capital IV. With $645 million in capital commitments, inclusive of LP and GP commitments, the Fund meaningfully exceeded its $500 million cover. The Fund received strong reups from its existing limited partners as well as significant commitments from new investors. Hark's limited partners include prominent U.S. insurance companies, public pension plans, and family offices. The total capital commitments for Fund IV represent more than a 60% increase compared to its Fund III, and an increase of approximately 220% compared to Fund II.

08:36 EDT Kopin expands medical technology portfolio with SLMs - Kopin announced an expansion of its medical technology portfolio with the introduction of its proprietary high-resolution, fast Spatial Light Modulators, or SLMs, into fluorescence super-resolution microscope systems for biomedical research. The company believes these advanced SLMs are invaluable components in fluorescence super-resolution microscope systems due to their ability to provide much higher resolution images, often down to the molecular leve.

08:36 EDT ReShape Lifesciences enters merger agreement with Vyome Therapeutics - ReShape Lifesciences and Vyome Therapeutics have entered into a definitive merger agreement under which ReShape and Vyome will combine in an all-stock transaction. The combined company will focus on advancing the development of its immuno-inflammatory assets and on identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market. Under the terms of the merger agreement, which has been unanimously approved by the boards of directors of both companies, existing ReShape stockholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's actual net cash at closing compared to a target net cash amount of $5 million. At the closing of the merger, ReShape will be renamed Vyome Holdings, Inc. and expects to trade under the Nasdaq ticker symbol "HIND," representing the company's alignment with the U.S.-India relationship. The board of directors of the combined company will be comprised of six directors designated by Vyome and one director designated by ReShape and executive management of the combined company will consist of Vyome's executive officers. Simultaneously with the execution of the merger agreement, ReShape entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., which is party to a previously disclosed exclusive license agreement with ReShape for ReShape's Obalon Gastric Balloon System. Pursuant to the asset purchase agreement, ReShape will sell substantially all of its assets to Biorad, including ReShape's Lap-Band System, Obalon Gastric Balloon System and the Diabetes Bloc-Stim Neuromodulation System, and Biorad will assume substantially all of ReShape's liabilities, for a purchase price of $5.16 million in cash, subject to adjustment based on ReShape's actual accounts receivable and accounts payable at the closing compared to such amounts as of March 31, 2024. The cash purchase price under the asset purchase agreement will count toward ReShape's net cash for purposes of determining the post-merger ownership allocation between ReShape and Vyome stockholders under the merger agreement. Simultaneously with the execution of the merger agreement, ReShape, Vyome, and Vyome's wholly-owned subsidiary, Vyome Therapeutics Ltd., entered into agreements with certain existing accredited investors, pursuant to which the investors have committed to purchase a minimum of $7.3 million in securities of ReShape, Vyome and Vyome's subsidiary. Under these agreements, certain accredited investors have agreed to purchase up to $5.8 million in shares of common stock of the combined company immediately following completion of the merger which may be upsized through additional investments. The price per share for the common stock of the combined company to be paid by the investors in the offering will be calculated as a 30% discount to the agreed upon valuation of the combined company at the closing of the merger and does not contain any warrants or other convertible features. ReShape and the investors are executing and delivering the subscription agreements in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and contemporaneously with the sale of the shares of common stock will execute and deliver a registration rights agreement requiring the combined company to register the resale of the shares of common stock issued in the offering. In order to facilitate the transactions contemplated by the merger agreement and asset purchase agreement, ReShape entered into an agreement with a majority of the holders of its outstanding series C preferred stock that will, subject to and contingent upon the completion of the merger and the asset sale, reduce the liquidation preference of the series C preferred stock from $26.2 million to the greater of $1 million, 20% of the purchase price paid for the asset sale, and the excess of ReShape's actual net cash at the effective time of the merger over the minimum net cash required as a condition to the closing of the merger as set forth in the merger agreement. The series C preferred stock would automatically terminate at the effective time of the merger, except for the right to receive the reduced liquidation preference. Completion of the merger and the asset sale are subject to certain closing conditions, including, among other things, approval by the stockholders of ReShape, the Securities and Exchange Commission declaring effective ReShape's registration statement registering the shares to be issued in connection to the merger, and the Nasdaq Stock Market's approval of the continued listing of the combined company in connection with the completion of the merger.

08:35 EDT Sera Prognostics' PreTRM test reduces neonatal morbidity, mortality by 18% - Sera Prognostics announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the Avert Preterm Trial. Previously, Sera reported that both co-primary outcomes-reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay-met their endpoints, and the improvements in outcome with a PreTRM test-and-treat approach were statistically significant. Results from the trial indicated: an 18% reduction in severe neonatal morbidity and mortality; a 7-day reduction in mean neonatal hospital length of stay; increased average gestational age at birth before 32 weeks of 2.48 weeks; and a 28-day reduction in neonatal length of hospital stay for babies born before 32 weeks' gestation, reducing time spent in the hospital for those at risk of earliest delivery. The manuscript also reports that neonatal morbidity and mortality and hospital and NICU length of stay were significantly reduced in the entire intent-to-treat population. The test and treat strategy was associated with a decreased odds of preterm birth and spontaneous preterm birth at various gestational ages at birth and an average NICU length of stay savings of 0.6 days per pregnancy across all pregnancies tested.

08:33 EDT Smart for Life announces appointment of Walters as CMO - Smart for Life announced that it has appointed Jessica Walters as the Company's new Chief Marketing Officer, CMO. Walter's appointment as CMO is believed by management to position Smart for Life for long term growth and utilize the Company's IP from its acquisitions to increase sales opportunities across its portfolio. "Our appointment of Jessica Walters as CMO represents a strategic effort to broaden our reach and strengthen our position in the Health and Wellness industry," stated Darren Minton, CEO of Smart for Life. "Ms. Walters is a highly seasoned digital marketing executive who has provided comprehensive consulting services for a broad range of companies in various industries prior to her appointment. Her mandate at Smart for Life includes utilizing the core IP from our acquisitions and various marketing platforms to enhance our sales capabilities."

08:32 EDT Latham Group, Poolside Tech launch The Attendant - Latham Group announces the launch of The Attendant, an automation system for inground, Latham fiberglass pools, in partnership with Poolside Tech, a leader in smart pool technology. "We are excited to partner with Poolside Tech to bring The Attendant to the entire range of Latham fiberglass pools," said Scott Rajeski, President and CEO of Latham. "This smart pool automation technology brings the pool industry into the digital age and helps to drive Latham's mission of becoming the center of your backyard lifestyle by improving pool ownership for our consumers."

08:31 EDT Meta to remove more Facebook, Instagram posts that attack 'Zionism' - Meta plans to remove more Facebook and Instagram posts that attack "Zionism" or threaten "Zionists" when the term is conflated with Jewish people or Israelis, the company said in a blog post on Tuesday. "We will remove content attacking 'Zionists' when it is not explicitly about the political movement, but instead uses antisemitic stereotypes, or threatens other types of harm through intimidation, or violence directed against Jews or Israelis under the guise of attacking Zionists," Meta wrote. Meta previously considered "Zionism" as a proxy for Jewish people in very narrow or explicit cases, like if Zionists were compared to rats, according to the blog post. Reference Link

08:27 EDT Globavend adds New Zealand Post as last-mile delivery supplier - Globavend announced the inclusion of New Zealand Post (NZ Post) as one of its last-mile delivery suppliers in New Zealand. NZ Post, a state-owned enterprise with the New Zealand Government as its sole shareholder, has a long-standing history of providing postal services across New Zealand. In May 2024, NZ Post commenced its first trial shipment for Globavend, marking the beginning of their collaboration in last-mile delivery services in New Zealand.

08:23 EDT Ensysce Biosciences hosts IASP 2024 Symposium - Ensysce Biosciences will host a symposium at the International Association for the Study of Pain 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: 'Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen, Professor of Aalberg University of Medicine, Denmark, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, two leading authorities on pain, pain treatment and analgesic drug development. Overall objectives of the session are to understand the current landscape for acute and severe pain treatment. Speakers will discuss current trends in severe pain associated with surgery and cancer progression, review drug use and abuse, and then examine the safety and effectiveness of PF614 and PF614-MPAR as indicated by clinical data results and how the leading agents are positioned for future clinical study.

08:21 EDT 374Water appoints Deborah Cooper as CAO, chief of staff - 374Water announces the appointment of Deborah Cooper as Chief Administrative Officer and Chief of Staff. In her new role, Cooper will focus on business operations and strategic planning to enhance 374Water's ability to scale operations in the near term. She will work closely with CEO Chris Gannon on strategic initiatives while providing leadership and guidance across the Company's business units on all facets of the business including identifying key market opportunities, ensuring the organization is optimized to execute on deliverables from an operational, financial and human capital perspective and playing a pivotal role in stakeholder engagement, technology efficacy and expansion initiatives. Previously, Cooper held roles including Chief People Officer at National Fire and Safety and Chief Human Resources Officer & Integration Leader at Oswald Companies and Unison Risk Advisors

08:19 EDT CareCloud proposes amendment to terms of Series A preferred stock - CareCloud has begun soliciting proxies from the holders of its 11% Series A Cumulative Redeemable Perpetual Preferred Stock to approve an amendment to the Company's Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock. Under the Preferred Stock Proposal, holders of Series A Preferred Stock would receive similar change of control protections to those afforded to holders of the Company's 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock. The future dividends of the Series A Preferred Stock would mirror that of the Series B Preferred Stock, and the Company would, going forward, have the right to exchange the shares of Series A Preferred Stock for shares of common stock at the liquidation preference value of $25 per share, plus any accrued and unpaid dividends. The Proxy. On July 8, 2024, the Company filed a Definitive Proxy Statement relative to a Special Meeting of Series A Preferred Shareholders. This Proxy, in turn, is the result of the capital structure analysis that was performed by Citizens JMP, which was prompted by the Board's exercise of its fiduciary duty in response to an unsolicited indication of interest to acquire the Company. The Proxy seeks approval of the Preferred Stock Proposal which, if approved by holders of two-thirds of the Series A Preferred Stock, would modify the terms of the Series A Preferred Stock by: Change of Control Rights. Adding a change of control provision, as presently afforded to holders of Series B Preferred Stock, that would require an acquirer of a controlling interest in the Company's common stock to redeem the Series A Preferred Stock in exchange for shares of the Company's common stock based on a $25 per share liquidation preference plus any accumulated and unpaid dividends; Equivalent Dividend Rate. Changing the dividend to 8.75% per annum; and Exchangeability. Introducing an exchange feature that would enable the Company, at its option, to cause the outstanding shares of the Series A Preferred Stock, at any time, to be automatically exchanged for a number of shares of common stock equal to the quotient obtained by dividing the sum of the $25.00 per share liquidation preference, and the amount of any accumulated and unpaid dividends on such share of Series A Preferred Stock being exchanged by the volume weighted average price of the shares of the Company's common stock.

08:18 EDT American Shared Hospital signs JV agreement for Gamma Knife facility - American Shared Hospital Services announced that it has signed a joint venture, JV, agreement to partner in a Gamma Knife treatment facility in Guadalajara, Mexico. AMS has signed a Joint Venture agreement with Hospital San Javier to establish a Mexican JV to treat public and private cancer patients. AMS and HSJ will hold 70% and 30% ownership interests, respectively. The new Joint Venture will be upgrading HSJ's existing Gamma Knife Perfexion system to an Esprit, Elekta's newest Gamma Knife radiosurgery system. "We believe that this joint venture with HSJ is a testament to AMS' global expansion plans and is ripe with opportunity. This is an exciting transaction for AMS, and the second expansion of our international strategy into Mexico, where we will soon begin treating patients with our state of the art Elekta Linear Accelerator Versa HD at our AB Radiocirugia y Radioterapia facility in Puebla. These two operations are in addition to our existing international Gamma Knife centers in Peru and Ecuador," said Ray Stachowiak, Executive Chairman and CEO of American Shared Hospital Services.

08:16 EDT SHF Holdings exits $3.1M loan in default - SHF Holdings exited a $3.1 million loan that was previously in default. In addition to the full repayment of the principal, Safe Harbor received $202,175 in accrued interest, all of which will be reallocated into its lending and credit line capacity. The $3.1 million first-lien loan was originated in 2021 and secured by Class A industrial real estate in the Denver metropolitan area. The strength of the underlying fundamentals of the property helped facilitate a successful exit of the loan, further demonstrating the soundness of Safe Harbor's underwriting approach. This was the only loan in the portfolio in default as of March 31, 2024.

08:16 EDT KKR and partners invest in enterprise data platform Nasuni - KKR will 'participate as a new investor in a strategic growth investment led by Vista Equity Partners, a global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses, in Nasuni, an enterprise data platform for modern hybrid cloud environments. The new investment, which values Nasuni at approximately $1.2B. Nasuni is a provider of file data services. The Nasuni File Data Platform is a cloud-native replacement for traditional network attached storage and file server infrastructure. Nasuni also eliminates the need for complex legacy file backup, disaster recovery, remote access, and file synchronization technologies. Nasuni's data platform is used by over 850 companies spanning 70 countries. KKR is making the investment through its Next Generation Technology III Fund.

08:16 EDT Smith & Nephew announces Orthopaedics for All initiative - Smith+Nephew announces its Orthopaedics for All initiative - a global advisory board established to amplify diversity by building equity, breaking biases, and inspiring inclusion for individuals wishing to pursue a career in orthopaedic surgery. The disparity of women in the field of orthopaedic surgery compared to men is staggering. According to multiple studies, only 15% of all orthopaedic residents were women and just 7.4% were practicing orthopaedic surgeons in the United States during 2022. Several factors may contribute to this inequity including greater vulnerability to work-family conflict, less supportive references than their male counterparts, and less national research funding compared to men. Smith+Nephew aims to address these long-standing challenges headfirst and help set new standards in patient centric care. The Smith+Nephew Orthopaedics for All global advisory board is comprised of approximately twenty leading female key opinion leaders and surgeons in the adult hip and knee orthopaedic reconstruction segment and includes representatives from all over the world. Board members must have a minimum of two years post-fellowship experience in reconstructive surgery, a mix of both academic and private practice experience, and an interest in gender diversity and inclusion initiatives. Orthopaedics for All will also drive awareness in the greater orthopaedic surgeon community around the technical skills and competence female orthopaedic surgeons possess.

08:14 EDT BioAffinity reports 217% revenue growth for CyPath Lung in Q2 - bioAffinity Technologies raised its full-year forecast for sales of CyPath Lung in the company's test marketing program by 85% and reported 217% growth in second-quarter sales over first quarter 2024, outpacing the forecast previously reported in May by 75%. CyPath Lung fulfills the need for a noninvasive test for the early detection of lung cancer and is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule. The lung cancer diagnostics market is projected to reach $4.7 billion by 2030, according to ReportLinker's industry analysis. The accelerating growth of CyPath Lung sales builds on the foundation laid in 2023 when bioAffinity launched a strategic beta marketing program in Texas after obtaining a CPT code and Medicare reimbursement for CyPath Lung. This initiative included hiring seasoned sales executives to educate physicians on the benefits of CyPath Lung for patients at risk for lung cancer. Additionally, private insurers have begun reimbursing for the test, which is billed at $1,900 by Precision Pathology Laboratory Services or PPLS, a wholly owned subsidiary of bioAffinity. PPLS is projected to generate between $9.2 and $9.6 million revenue in 2024, including sales of CyPath Lung. "We strategically focused our marketing efforts on our home state of Texas as we launched CyPath Lung, a noninvasive test that has shown 92% sensitivity and 87% specificity in detecting cancer in the lung for people who have pulmonary nodules 20 millimeters or less," bioAffinity Technologies President and CEO Maria Zannes said. "The strategic decision to begin our commercial launch in Texas allows us to hone our message, improve operations and prepare for a broader market launch now scheduled for the fourth quarter of 2024."

08:13 EDT Patients more likely to lose weight with Mounjaro than Ozempic, study says - Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide, or Ozempic, and tirzepatide, Mounjaro, has been published in JAMA Internal Medicine. In the study published in JAMA Internal Medicine, Truveta Research compared weight loss outcomes for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes Ozempic and Mounjaro, respectively. In this study, Truveta Research studied patients with overweight or obesity initiating either semaglutide or tirzepatide between May 2022 and September 2023. The team used "multiple rigorous methods (including propensity score matching) to achieve a well-balanced analytic cohort of more than 18,000 patients to appropriately evaluate the effectiveness of semaglutide compared with tirzepatide for weight loss," Truveta stated. The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss: Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss; 2.5 times more likely than those taking semaglutide to achieve 10% weight loss; And 3.2 times more likely than those taking semaglutide to achieve 15% weight loss. "GLP-1 medications have dramatically increased in use by patients with and without type 2 diabetes in the past year, yet little real-world data exist to compare the effectiveness of two of the most common medications, semaglutide and tirzepatide. That's what makes today's study findings so exciting and important. Because Truveta Data provides timely, complete EHR data - including prescriptions and medication dispense data - that captures a large and diverse patient population, we've been able to compare the head-to-head effectiveness of these two important medications for weight loss in advance of smaller randomized clinical trials. This study can help to inform patient care and outcomes today, not months from now," said Tricia Rodriguez, PhD, MPH principal applied scientist, Truveta Research, and lead author on the paper. Novo Nordisk (NVO) markets Ozempic and Eli Lilly (LLY) markets Zepbound. Reference Link

08:12 EDT Intensity Therapeutics doses first patient in Phase 3 sarcome study - Intensity Therapeutics announced that the first U.S. patient has been dosed in the company's Phase 3 study to treat metastatic sarcoma. The trial is a superiority study testing INT230-6 as monotherapy compared to the investigator's choice of three current standard-of-care systemic chemotherapy drugs in second or third-line metastatic, recurrent, or inoperable soft tissue sarcomas. The global Phase 3 study is expected to enroll approximately 333 patients. The primary endpoint is overall survival. The Phase 3 initiation follows reported data from the Company's Phase 1/2 trial, where INT230-6 showed tumor-killing and immune-activating properties with increased survival in metastatic disease.

08:11 EDT Arcutis Biotherapeutics provides update on sNDA for roflumilast cream 0.15% - Arcutis Biotherapeutics announced that the Company has been in communication with the U.S. Food and Drug Administration, FDA, regarding its supplemental New Drug Application, sNDA, for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis for adults and children down to the age of 6. The FDA has indicated that they are working to finalize the action letter and have not indicated they would extend the Prescription Drug User Fee Act, PDUIFA, goal date of July 7, 2024. "We would like to emphasize that the FDA has not requested any additional information related to our sNDA. This speaks to the completeness and quality of our submission, as we have worked diligently to provide all necessary data and meet all regulatory requirements," said Frank Watanabe, president and CEO of Arcutis. "We are in close contact with the FDA and anticipate receiving our action letter soon. Pending approval, we look forward to delivering this new innovative treatment in roflumilast cream to the millions suffering from atopic dermatitis."

08:10 EDT SAITECH announces signing of two MoU for HEATNUC products - SAI.TECH Global announces the signing of two Memorandums of Understanding, MoU, for HEATNUC products aimed at strengthening cooperation within the small modular reactor industry. These MoUs are set to enhance SAI.TECH's competitiveness in the Middle Eastern and international markets while increasing localization efforts in the region. The first MoU, signed with Suzhou East Instrument Technology Co., Ltd., signifies a strategic partnership focused on the export of electrical and instrumentation control system equipment for nuclear power and engineering projects. The second MoU, inked with Kunshan Three-Dimensional Heat Exchanger Co., outlines plans for joint production of nuclear and Small Modular Reactor equipment and components.

08:08 EDT SunCar Technology wins bid for China Construction Bank car wash service - SunCar Technology announced the successful bid for the China Construction Bank - CCB - Yunnan Branch Long Card Car Wash Service project. Since 2023, SunCar has been forging strategic partnerships with multiple CCB branches, including Fujian, and now Yunnan, to provide Long Card car wash services.

08:08 EDT Arlo Technologies: AI-powered subscription service surpasses 4M paid accounts - Arlo Technologies announced its AI-powered subscription service has surpassed a milestone of 4M paid accounts. Arlo's continued subscription growth is a testament of the benefits and value that consumers place on its subscription plans and the overall power of its service business.

08:07 EDT Annovis Bio announces addition of four new executives to leadership team - Annovis Bio announces the addition of four accomplished professionals to its executive team. Mark White Appointed Chief Business Officer - Currently a member of our Board of Directors, Mark White brings a wealth of global pharmaceutical marketing, business development, and sales experience to his new role as Chief Business Officer. Alexander Morin, Ph.D., Appointed Director of Strategic Communications - He has previously held the position of account executive at a boutique public relations firm. Hilda Maibach appointed Senior Vice President of Statistics - Maibach brings more than 30 years of experience in all aspects of clinical and observational studies in Oncology, Infectious Disease, Metabolic disorders and Central Nervous System Disorders. Blake Jensen appointed Head of Quality - Blake Jensen has over 20 years of experience in Quality within contract service providers and emerging biopharma companies, as well as previously working as an investigator for the U.S. FDA.

08:06 EDT Wendy's signs franchise agreements to enter Republic of Ireland, Romania - Wendy's announced the signing of two new development agreements with franchisees in the Republic of Ireland and Romania. These franchisees plan to support Wendy's expansion goals to develop hundreds of restaurants across Europe over the next decade, beginning in 2025. The company is also actively recruiting franchisee candidates in European markets to help expand its restaurant footprint across the continent. Wendy's re-entered the U.K. in 2021, which serves as the foothold for growth across Europe. The company expects to see up to 50 restaurants in the market by year-end and expects to grow the brand in the U.K. to 400 restaurants over time. Wendy's international presence represents 70% of the brand's planned expansion through 2025.

08:06 EDT Genetic Technologies to enter Canadian, New Zealand markets - Genetic Technologies announced the introduction of geneType's suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType's recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, the company is expanding its international presence four-fold in the second quarter of 2024. The geneType risk assessment test distribution in the new territories will be directed by Stayhealthy Canada and Stayhealthy New Zealand, respectively.

08:05 EDT Clene announces 1-for-20 reverse stock split - Clene announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. Eastern Time, on July 11, 2024. Beginning with the opening of trading on July 11, 2024, Clene's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the Company's existing trading symbol "CLNN." The CUSIP number for the Company's publicly traded warrants will not change. The reverse stock split is intended to enable Clene to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market.

08:04 EDT TeraWulf announces early debt payoff - TeraWulf announced the full repayment of its term loan ahead of schedule, eliminating all outstanding debt. The final payment, totaling $77.5 million, which includes pre-payment fees and accrued interest, underscores TeraWulf's commitment to financial prudence and resiliency. After paying off the term loan, the Company has no outstanding debt and has thereby maximized financial flexibility to scale and deploy its valuable and low-cost energy infrastructure for bitcoin mining and high-performance computing/AI applications.

08:04 EDT UL Solutions acquires Germany-based TesTneT, no terms - UL Solutions announced the acquisition of TesTneT Engineering GmbH, a Germany-based company in hydrogen component and system testing, deepening our expertise in alternative fuels and enhancing our ability to impact global decarbonization efforts..."Hydrogen technology is increasingly important in the transition to sustainable energy, and as a global safety science leader in the energy transition, this is a promising field for us," said Jennifer Scanlon, president and CEO of UL Solutions. "The addition of TesTneT will enable us to better collaborate with our customers to help advance the safe adoption of hydrogen-powered technologies globally." The transaction closed on July 8, 2024. Terms of the transaction are not being disclosed at this time.

08:03 EDT RedHill Biopharma terminates license agreement for Aemcolo - RedHill Biopharma announced the mutual decision with Cosmo Technologies to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea. The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024. Per the terms of the License Agreement, RedHill will immediately cease any Aemcolo commercialization of Aemcolo upon termination of the License Agreement, at which point all rights previously ascribed in the License Agreement to RedHill will revert to Cosmo.

08:02 EDT Kiniksa commence enrollment in Phase 2b trial of abiprubart - Kiniksa Pharmaceuticals announced that it has commenced enrollment of the Phase 2b clinical trial of abiprubart in Sjogren's Disease. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 interaction. "Sjogren's Disease is a debilitating, chronic autoimmune disorder currently with no FDA-approved therapies. Commencing the next phase of development of abiprubart in Sjogren's Disease is an important step forward for patients," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "This Phase 2b clinical trial builds on external mechanistic proof-of-concept as well as learnings from our own prior clinical data. Additionally, we believe abiprubart has the potential for differentiation in addressing unmet need through convenient subcutaneous administration. Importantly, our current operating plan includes clinical development of abiprubart in Sjogren's Disease, and the company expects to remain cash flow positive on an annual basis."

08:02 EDT Coda Octopus reports $906k Engineering Services order - Coda Octopus Group reported that its Salt Lake City based Defense Engineering Services Business, Coda Octopus Colmek, recently received one of the orders that had been expected and delayed during the first six months of fiscal 2024. This order has a contract value of $906k and relates to one of the programs that it has been servicing for over 25 years.

07:47 EDT Jazz Pharmaceuticals promotes Samantha Pearce to Chief Commercial Officer - Jazz Pharmaceuticals announced that Samantha Pearce, SVP, Europe and International, has been promoted to Chief Commercial Officer effective August 1, 2024. Pearce joined Jazz as SVP, Europe and International, in 2020. From March 2010 to December 2019, Pearce held general management positions with Celgene, most recently as vice president and general manager of international markets. Prior to that, from August 2002 to March 2010, she served in commercial management positions at AstraZeneca, culminating in her role as director of specialist care. Prior to August 2002, she worked for DuPont Pharmaceuticals.

07:41 EDT Sonoma Pharmaceuticals announces new distributor in Ukraine - Sonoma is expanding its distributor base in Europe by adding a new partnership with Smart Healthcare Company s.r.o. for the distribution of its Microdacyn60 wound care products into Ukraine. SCH, based in Slovakia, will work with DANA MC, a leading supplier of the medical market in Ukraine, to distribute Sonoma's Microdacyn60 solution and hydrogel into this territory.

07:40 EDT Helen of Troy falls 26% to $65.98 after Q1 results miss, FY25 guidance lowered

07:37 EDT Amesite announces models powering NurseMagic show 93% accuracy when tested - Amesite announced that its proprietary models that power its NurseMagic app have demonstrated a 93% accuracy when tested against NCLEX test questions. Accuracy is essential for the growing number of nurses using the app. The recently launched app has experienced rapid adoption by nurses following its release to the general public, and utilizes Amesite's proprietary technology to provide useful information and assistance in real time, targeting over 5.2 million nurses in the US. The foundational model that powers NurseMagic achieved a 93% accuracy rate when tested with questions from two leading NCLEX prep providers' test banks. NurseMagic tools are guided by nursing ethics and provide assistance in areas ranging from nurse notes to patient communication to symptom analysis.

07:36 EDT Prairie Operating Co. announces launch of its development program - Prairie Operating announced plans to commence its initial drilling program in August 2024, starting with an 8-well pad on the recently acquired bolt-on acquisition, "Shelduck South". The Shelduck South development will consist of eight two-mile lateral wells across 1,280 mineral acres, targeting the Niobrara B and C formations. The Company has contracted a drilling rig from Precision Drilling and secured various oil field service providers to perform all drilling and completion operations. The Precision drilling rig is capable of operating on electric line power and is equipped with natural gas generators with battery assist to minimize emissions. Prairie anticipates the wells will be drilled, completed, and turned to production in Q4 2024.

07:35 EDT Redwire developing advanced thruster tech to support DoD small satellite supply - Redwire Corporation announced it has signed a strategic cooperation agreement, SCA, with in-space propulsion leader Phase Four to build and deliver advanced thruster technology designed for reliable, high-volume production to meet the surge in demand across national security space programs. The SCA provides a framework which allows for joint development of this advanced thruster. Redwire and Phase Four will design and develop a reliable and efficient Hall Effect Thruster, HET , called the Valkyrie Thruster, based on an existing design."... "The partnership between Phase Four and Redwire provides both civilian and military space operators another stable and reliable domestic source of electric propulsion systems," said Steve Kiser, Phase Four CEO. ...Redwire and Phase Four will leverage their expertise to manufacture the power processing unit hardware, thruster, propellant management software, and software control, which both companies will integrate into flight panels. Redwire will leverage its business operations at scale, marketing resources, and extensive heritage as a trusted space systems supplier to bring this in-space propulsion system to market. The Valkyrie thrusters are anticipated to go into full rate production in 2025.

07:32 EDT CalciMedica enrolls first patient in trial of Auxora in acute kidney injury - CalciMedica announced that the first patient has been dosed in KOURAGE, the company's Phase 2 trial evaluating Auxora for the treatment of severe acute kidney injury with associated acute hypoxemic respiratory failure. KOURAGE is a randomized, double-blind, placebo-controlled study expected to enroll approximately 150 patients with Stage 2 and 3 AKI who have AHRF and will randomize patients to receive 5 daily doses of Auxora or placebo. The study will assess patients up to day 30 following the final dosing to evaluate the number of days alive without the need for a ventilator or dialysis. The study's secondary endpoints will include a composite measure of all-cause mortality, decline in estimated glomerular filtration rate and the occurrence of dialysis over a 90-day period. Topline data from KOURAGE are expected in 2025.

07:27 EDT Interactive Strength enters distribution agreement with MEFITPRO - Interactive Strength announced that, it has secured exclusive distribution and a six-figure initial order for CLMBR in the fast-growing Gulf region with MEFITPRO.

07:24 EDT Gryphon Digital Mining sees 84 bitcoin produced in Q2 - Gryphon Digital Mining released its unaudited operational update for June 2024 and Q2/24. Key highlights: Set a new company record in quarterly hashrate of 899 PH/s in Q2/24, a 20% increase over Q2/23; Record monthly performance in energy efficiency at 28.5 joules per terahash in June; Expect to have produced approximately 84 bitcoin in the second quarter; Projected approximately $5.5 million in value based on an average quarterly bitcoin price of $65,916; Achieved bitcoin efficiency of 25 BTC/EH for the month of June; 99.4% mining fleet average up time in June; Qualified for inclusion in the Russell Microcap Index, which was effective as of July 1st; Scope 1 and Scope 21 operations continue to be 100% electrified by zero-carbon emitting hydro power. "The second quarter of 2024 was significant for Gryphon as we achieved company records in hashrate and energy efficiency," noted Rob Chang, CEO of Gryphon. "While the company is only five months removed from debuting on the Nasdaq in February of this year, we continue to set company records as we move forward as a public company. We expect to have earned bitcoin valued at approximately $5.5 million for the second quarter of the year, based on an average bitcoin price of $65,916. This includes the production of approximately 22 bitcoin in the month of June at an average bitcoin price for the month of $66,170," continued Mr. Chang. "Gryphon continues to improve its efficiency levels by setting a new company record of 28.5 J/T for the month of June and combined with the realization of our inclusion in the prestigious Russell Microcap Index effective July 1st, we believe the Company is maintaining its upward trajectory in the bitcoin mining industry."

07:21 EDT Neo-Concept receives Nasdaq notification regarding minimum bid price rule - Neo-Concept International Group announced that, on July 8, 2024, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that based on the closing bid price of the Company for the period from May 21, 2024 to July 5, 2024, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company's ordinary shares. Nasdaq has provided the Company with an 180 calendar days compliance period, or until January 6, 2025, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq's continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.

07:18 EDT CorVel's Symbeo partners with Amazon Business - Symbeo, a CorVel Company (CRVL), has partnered with Amazon (AMZN) Business App Center to deliver its RapidInvoice, an AI-enabled optical character recognition product. The partnership is a significant stride into the mid-market and SMB market, as more companies are drawn to e-commerce platforms such as Amazon's B2B marketplace. This move allows customers to leverage wholesale pricing for goods and services, with the added advantage of integrated payment reconciliation to financial systems, promising a future of enhanced efficiency and cost-effectiveness.

07:16 EDT SpringBig announces partnership with Native Roots - Springbig announced the recent signing with Native Roots, Colorado's largest independently held vertically integrated cannabis company. Native Roots has chosen Springbig to elevate their customer experience and streamline their marketing efforts. With this collaboration, Springbig will provide Native Roots with advanced technological solutions to improve communication and engagement with their customers, ensuring an unmatched customer experience.

07:15 EDT Gilat receives over $10M contract extension for cellular backhaul services - Gilat Satellite Networks announced that Gilat received a follow-on 6 year order for over $10M from Internet Para Todos to deliver Cellular Backhaul services across rural areas in Peru.

07:12 EDT Duolingo completed acquisition of Hobbes - Duolingo announced that it has completed the acquisition of Hobbes, an animation and motion design studio based in Detroit. This is Duolingo's second acquisition, following the successful 2022 acquisition of Gunner, another Detroit-based design and animation studio that is affiliated with Hobbes. "Design is a critical part of Duolingo's success, particularly our use of character illustration and animation, which really accelerated since adding Gunner to our team. Now we'll be able to accelerate our use of motion-design by adding Hobbes' unique talents to our Design team," said Ryan Sims, Chief Design Officer, Duolingo. "We're investing in the belief that a more animated product experience is more fun and delightful, and leads to better learning outcomes."

07:11 EDT West Red Lake reports drill results from Madsen Mine - West Red Lake Gold reports drill results from its 100% owned Madsen Mine located in the Red Lake Gold District of Northwestern Ontario, Canada. This round of drill results from the Madsen Mine were all drilled from underground on the North Austin Zone, which represents a new area of high-grade mineralization extending the current Madsen resource to the northeast. This program was designed to expand the North Austin zone down-plunge and to the northeast. The North Austin drilling update provided in this news release builds on the positive drill results previously announced on May 21, 2024 and Feb 7, 2024. The North Austin Zone sits adjacent to existing underground development marking it as a high caliber, near-surface target that could potentially be developed early during future mine restart and production. The North Austin Zone remains open down-plunge and along strike to the northeast and will continue to be a priority expansion target as underground drilling continues. HIGHLIGHTS: Hole MM24X-03-5195-018 Intersected 10m @ 13.40 grams per tonne gold, from 82m to 92m, Including 1.0m @ 17.75 g/t Au, from 82m to 83m, also Including 1.0m @ 85.61 g/t Au, from 88.31m to 89.31m, also Including 1.0m @ 14.05 g/t Au, from 89.31m to 90.31m. Hole MM24X-03-5127-012 Intersected 3m @ 12.21 g/t Au, from 58m to 61m, Including 1m @ 32.84 g/t Au, from 60m to 61m. Hole MM24X-03-5195-015 Intersected 16.98m @ 3.12 g/t Au, from 82m to 92m, Including 0.98m @ 11.78 g/t Au, from 72.52m to 73.50m, also Including 1.0m @ 14.69 g/t Au, from 74.45m to 75.45m, also Including 0.79m @ 15.60 g/t Au, from 87.21m to 88.00m. Shane Williams, President & CEO, stated, "The North Austin drilling continues to deliver meaningful results which is a testament not only to the quality of this resource area, but also to our technical team's understanding of the structural controls and ore shoot geometries in this emerging part of the Madsen deposit. With the team now working towards a planned mine restart in the second half of 2025, the drills at Madsen will continue to delineate and define the high-value mineral inventory needed to support that objective."

07:09 EDT Orthofix gets 510 clearance for 1st implant of Fitbone Transport & lengthening - Orthofix Medical announced the 510 k clearance and first U.S. implant of the Fitbone Transport and Lengthening System. Used to treat large bone defects in the femur and tibia due to trauma, infectious or malignant conditions, the device is the only intramedullary nail designed to transport or lengthen the bone through a single surgery....The Fitbone(TM) Transport and Lengthening System, used to treat large bone defects in the femur and tibia due to trauma, infectious or malignant conditions, is the only intramedullary nail designed to transport or lengthen the bone through a single surgery. "Patients with defects to the femur and tibia can be difficult to treat and often have undergone multiple prior surgeries," said Dr. David Frumberg, an orthopedic surgeon and Director of the Limb Restoration and Lengthening Program in New Haven, Conn., who performed the first U.S. implantation. "The Fitbone Transport and Lengthening System is a game-changing new option that enables bone to be transported across the defect, allowing very challenging problems to be treated without multiple follow-up surgeries."

07:08 EDT Plug Power delivers, commissions over 95 MW of electrolyzer capacity globally - Plug Power announces that it has begun installing and commissioning electrolyzer systems worldwide, with many already operational and producing hydrogen today. To date over 95 MW of Plug electrolyzer systems are in operation or commissioning at sites across the world, setting a new PEM electrolyzer capacity milestone in the hydrogen industry. The location of these systems spans multiple regions in North America, Europe, Africa, Asia, New Zealand and India. "This milestone represents a significant achievement for Plug, underscoring our leadership in delivering proven technology to meet the growing demand for hydrogen worldwide," said Plug CEO, Andy Marsh. "Deploying electrolyzer systems across multiple continents and producing over 1,500 metric tons of hydrogen, is a clear example that at Plug, we're not just talking about the future of hydrogen - we're actively building it today."

07:07 EDT Cyngn granted patent for autonomous vehicle adaptive decision making method - Cyngn announced the notice of allowance for a new patent for the company's autonomous vehicle - AV - solutions. This patent introduces an adaptive decision making method designed to enhance how AVs operate in real-world environments in response to other detected objects. This patent describes a method to apply driving rules and rules associated with detected objects to inform decisions of the AV.

07:05 EDT Akoustis secures $8M in volume XBAW orders with Tier-1 customer - Akoustis Technologies announced that the Company has received $8M in new orders from a Tier-1 customer to satisfy the customer's demand for four Wi-Fi Access Points, which are either currently in production or ramping into production in the second half of calendar year 2024. The purchase orders provide a significant backlog, and the Company plans to deliver millions of parts over the next six months to support the new demand for two Wi-Fi 6E APs that have been in production over the past year and two new Wi-Fi 7 programs ramping into production.

07:05 EDT Athira Pharma announces last patient completed dosing in LIFT-AD trial - Athira Pharma announced the completion of dosing for the last patient in the Phase 2/3 LIFT-AD clinical trial evaluating fosgonimeton in people with mild-to-moderate Alzheimer's disease, AD. The Company is now targeting to report topline results from the LIFT-AD trial by the end of the third quarter of 2024 and has been invited to discuss the fuller data set during an oral presentation on October 29, 2024, at the 17th Clinical Trials on Alzheimer's Disease, CTAD, conference taking place from October 29 - November 1, 2024, in Madrid, Spain. LIFT-AD is a randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of fosgonimeton, which is designed to positively modulate the neurotrophic hepatocyte growth factor system to protect and preserve neuronal health and function. Notably, 85% of eligible clinical trial participants in LIFT-AD and the Phase 2 ACT-AD trial elected to enroll in Athira's open label extension study, which enables participants to either remain on fosgonimeton or, for those in the placebo group, begin fosgonimeton treatment. Currently, more than 70 patients are continuing fosgonimeton treatment beyond 18 months, with nearly 50 patients beyond two years, reflecting a long-term participation rate beyond what might be expected in a progressive mild-to-moderate Alzheimer's disease population

07:03 EDT Harrow enters 340B Prime Vendor Program contract with Apexus - Harrow announced that it has entered into an agreement with Apexus to make Iheezo 3% and other Harrow products available through its 340B Prime Vendor Program. Iheezo, indicated for ocular anesthesia, is a low-viscosity topical ocular anesthetic gel with reliable efficacy, a proven safety profile, and simple administration. Other Harrow products available through the program include Vigamox, a topical eye drop for bacterial conjunctivitis, and Ilevro, an ocular nonsteroidal anti-inflammatory topical eye drop for pain and inflammation.

07:03 EDT BioCryst announces ORLADEYO approval in Peru - BioCryst Pharmaceuticals announced that the General Directorate of Medicines, Supplies and Drugs in Peru has granted approval for oral, once-daily ORLADEYO for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older. BioCryst has an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO in the pan-Latin America region. Under the terms of the agreement, Pint is responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in LATAM. ORLADEYO has previously been approved in this region by regulatory agencies in Chile, Argentina, Brazil and Mexico.

07:02 EDT AerCap to lease ten new Airbus A321neo aircraft to Turkish Airlines - AerCap (AER) has reached agreement with Turkish Airlines for the lease of ten new Airbus (EADSY) A321neo aircraft.

07:00 EDT Q32 Bio completes enrollment in SIGNAL-AD clinical trial - Q32 Bio announced that it has completed enrollment in the SIGNAL-AD Phase 2 clinical trial of bempikibart for the treatment of persistent, moderate-to-severe atopic dermatitis, or AD. Bempikibart is a fully human anti-IL-7Ra antibody that is designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, both of which contribute to inflammation and injury in a diversity of autoimmune disorders.

06:54 EDT Golden Minerals receives continued listing non-compliance notice from NYSE - Golden Minerals was notified by the NYSE American that it was not in compliance with three of the NYSE American's continued listing standards. The company is not in compliance since it reported stockholders' equity of $0.6M as of March 31, and losses from continuing operations and/or net losses in its five most recent fiscal years. On July 6, 2023, the company submitted a plan to achieve compliance by December 6, 2024. On August 22, 2023, the NYSE Regulation staff accepted the plan and granted a plan period through December 6, 2024. The notification has no immediate effect on the company's common stock or its business operations.

06:52 EDT Viavi, TIP enter strategic collaboration - Viavi and the Telecom Infra Project, or TIP, announced a strategic collaboration aimed at expanding the testing capabilities of the Viavi Automated Lab-as-a-Service for Open RAN. Valor, made possible by a $21.7M grant from the U.S. National Telecommunications and Information Administration, or NTIA, Public Wireless Supply Chain Innovation Fund, or PWSCIF, provides fully-automated, open and impartial testing and integration for Open RAN. Valor provides a pathway to certification in the U.S. for new entrants, startups, and academia and ensures the interoperability, performance, and security of Open RAN components.

06:51 EDT Endeavour Silver reports Q2 production results - Endeavour Silve is pleased to report second quarter 2024 production of 1,312,572 silver ounces and 10,549 gold oz, for silver equivalent production of 2.2M oz. Total year-to-date production of 4.4M AgEq oz is tracking towards the upper range of the full year 2024 production guidance of 8.1M-8.8M silver equivalent ounces.

06:48 EDT Infosys announces five-year collaboration with Sector Alarm - Infosys (INFY) announced a strategic five-year collaboration with Sector Alarm, who are partially owned by global investment firm KKR (KKR), to transform their core enterprise business systems on the cloud. Through this collaboration, Infosys will work closely with Sector Alarm to migrate their disparate, on-premises Enterprise Resource Planning platform onto Microsoft Dynamics 365 Finance and Operations, helping them modernize their financial and business operating models.

06:46 EDT Unitil to acquire Bangor Natural Gas Company from Hope Utilities for $70.9M - Unitil announced that it has agreed to purchase Bangor Natural Gas Company from PHC Utilities, Inc., a subsidiary of Hope Utilities, Inc., for $70.9M on a debt-free basis, subject to customary adjustments for closing working capital and transaction expenses. Bangor's enterprise value represents a multiple of approximately 1.2 times its rate base. Upon the closing of the transaction, which is expected to occur by the end of the first quarter of 2025, Bangor will become a wholly owned subsidiary of Unitil. The transaction is subject to approval by the Maine Public Utilities Commission as well as other conditions to closing.

06:37 EDT 60 Degrees Pharmaceuticals' study of tafenoquine in babesiosis approved - 60 Degrees Pharmaceuticals announced ethics approval of an open label, expanded access study of the Arakoda regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis. The goal of the study is to confirm the findings of an 80% babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health in April and published in Clinical Infectious Diseases. Tafenoquine is approved for malaria prophylaxis in the United States under the product name Arakoda. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for such an indication. Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. Its symptoms include fevers, chills, sweats, and fatigue, and in severe cases, can be life-threatening. Incidence of the disease is rapidly rising, particularly in the Northeast. The company believes that the total accessible market through the end of patent protection in December 2035 in the U.S. for tafenoquine for babesiosis is 38,000.

06:32 EDT Hut 8 signs agreement for West Texas site with 205 MW capacity - Hut 8 has entered into a power purchase agreement and other definitive agreements for a site in West Texas with exclusive access to 205 megawatts of immediately available power capacity and land. The PPA and site give Hut 8 access to some of the lowest locational wholesale power pricing in North America. The site is positioned to support a variety of high-density compute applications, including Bitcoin mining and AI. Hut 8 is finalizing a commercialization plan for the site with the aim of maximizing its value. Upon closing, subject to the satisfaction of customary conditions, this transaction is expected to expand Hut 8's energy infrastructure platform to approximately 1.3 gigawatts of capacity owned and managed across self-mining, hosting, managed services, high performance computing, and power generation.

06:03 EDT Ceragon Networks announces multi-million-dollar order from ISP - Ceragon Networks announced a multi-million-dollar order from an American Internet Service Provider, or ISP. The deal extends a robust partnership spanning more than half a decade that leverages advanced Siklu by Ceragon technology to deliver broadband internet service across the United States.

06:02 EDT Sound Group names Enrome as independent auditor - Sound Group, formerly known as LIZHI Inc., announced that the appointment of Enrome LLP as the company's independent registered public accounting firm for the fiscal year ended December 31, 2023, effective July 9, 2024. The appointment has been approved by the audit committee of the company's Board of Directors. Enrome succeeds PricewaterhouseCoopers Zhong Tian LLP, the company's previous independent registered public accounting firm. PwC is committed to working with the company and Enrome to ensure a seamless transition.

05:42 EDT BP sees impairment charge of up to $2B on Q2 results - BP said expects to take an impairment charge of up to $2B to its Q2 results partly because of a review of refining activities in Germany it announced in March. The company said on Tuesday that it expects its Q2 results to be hit by "post tax asset impairments and one-off contract provisions of between $1B-$2B", which includes the hit from the scaling back of refining operations at the Gelsenkirchen refinery from 2025, due to high costs and declining demand for fuels. BP also said that lower refining margins would hit its earnings by $500M-$700M.

05:33 EDT Altair selected as EDA partner for Samsung Advanced Foundry Ecosystem - Altair has been selected as an electronic design automation, or EDA, partner for the Samsung Advanced Foundry Ecosystem, or SAFE. Through this collaboration, Altair and Samsung Electronics will combine Altair's EDA technology with Samsung Foundry's manufacturing capabilities to establish a semiconductor design and production process.

05:20 EDT Stellantis to offer 30 hybrid models this year, six more through 2026 - Stellantis is reacting to the quick ramp-up of customer orders in Europe for hybrid models, especially those with the newest eDCT advanced hybrid technology. The company will offer 30 hybrid models this year and plans to introduce six more through 2026. Stellantis achieved a 41% sales increase in EU30 hybrid models year-to-date 2024 versus year-to-date 2023 and expects an increase in customer take rate with the upcoming new launches.

05:13 EDT Mainz Biomed requests breakthrough device designation from FDA for CRC product - Mainz Biomed announced that it has submitted its application to the FDA requesting breakthrough device designation for its non-invasive next generation colorectal cancer, or CRC, product including the company's novel portfolio of mRNA biomarkers. Subject to the FDA's review, a breakthrough device designation could significantly accelerate approval.

05:06 EDT Agco opens clean energy laboratory in Finland - Agco announced the opening of the company's first clean energy laboratory. The lab is part of a 70-million-euro investment, or approximately $77M, in the Linnavuori plant in Nokia, and will support development and testing of innovative, sustainable battery and powertrain solutions for farm machinery.